|
|
| Line 4: |
Line 4: |
| {{CMG}} | | {{CMG}} |
| ==Overview== | | ==Overview== |
| * [[Evacetrapib]] has been proven to be a promising CETP inhibitor as it does not show any elevations in [[blood pressure]] or [[aldosterone]]/[[cortisol]] levels<ref name="pmid22362199">{{cite journal |author=Nicholls SJ |title=Evacetrapib |journal=[[Current Cardiology Reports]] |volume=14 |issue=3 |pages=245–50 |year=2012 |month=June |pmid=22362199 |doi=10.1007/s11886-012-0252-3 |url=}}</ref><ref name="pmid21957197">{{cite journal |author=Cao G, Beyer TP, Zhang Y, ''et al.'' |title=Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure |journal=[[Journal of Lipid Research]] |volume=52 |issue=12 |pages=2169–76 |year=2011 |month=December |pmid=21957197 |pmc=3220285 |doi=10.1194/jlr.M018069 |url=}}</ref>.
| | |
| * It increases [[HDL]]-C and decreases [[LDL]]-C levels in a dose dependent manner.<ref name="pmid22089718">{{cite journal |author=Nicholls SJ, Brewer HB, Kastelein JJ, ''et al.'' |title=Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=306 |issue=19 |pages=2099–109 |year=2011 |month=November |pmid=22089718 |doi=10.1001/jama.2011.1649 |url=}}</ref>
| |
| ==References== | | ==References== |
| {{Reflist|2}} | | {{Reflist|2}} |